Lung Cancer Diagnostics Market Study by CA Tests, HER2 Tests, ALK Tests, Angiogenesis Inhibitors, EGFR Mutation Tests, and KRAS Mutation Tests from 2024 to 2034

<p>Growing awareness about the importance of accurate and early diagnosis of cancer is set to drive global demand for lung cancer diagnostics, with the market reaching a value of <strong>US$ 2.98 billion</strong> in 2024. The global lung cancer diagnostics market has been projected to expand at a <strong>CAGR of 6.1%</strong> and end up at <strong>US$ 5.4 billion</strong> by 2034.</p><table><thead><tr><th>Report Attributes</th><th>Details</th></tr></thead><tbody><tr><td>Lung Cancer Diagnostics Market Size (2024E)</td><td>US$ 2.98 Billion</td></tr><tr><td>Forecasted Market Value (2034F)</td><td>US$ 5.4 Billion</td></tr><tr><td>Global Market Growth Rate (2024 to 2034)</td><td>6.1% CAGR</td></tr><tr><td>Market Share of EGFR Mutation Tests (2034F)</td><td>28.2%</td></tr><tr><td>South Korea Market Growth Rate (2024 to 2034)</td><td>7.5% CAGR</td></tr><tr><td>South Asia &amp; Pacific Market Share (2034F)</td><td>21%</td></tr><tr><td>Key Companies Profiled</td><td><ul><li>NeoGenomics Laboratories, Inc.</li><li>Illumina, Inc.</li><li>Danaher Corporation</li><li>Abbott Laboratories</li><li>Roche Holding AG</li><li>Quest Diagnostics Incorporated</li><li>Myriad Genetics, Inc.</li><li>Thermo Fischer Scientific, Inc.</li><li>NanoString Technologies, Inc.</li><li>QIAGEN N.V.</li></ul></td></tr></tbody></table><p>Country-wise Insights</p><table><thead><tr><th>Attribute</th><th>United States</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 915 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>5.8% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 1.6 Billion</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>China</th></tr></thead><tbody><tr><td>Market Value (2024E)</td><td>US$ 233.9 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>9.6% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 586.7 Million</td></tr></tbody></table><p>Category-wise Insights</p><table><thead><tr><th>Attribute</th><th>EGFR Mutation Tests</th></tr></thead><tbody><tr><td>Segment Value (2024E)</td><td>US$ 879.3 Million</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>5.6% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 1.52 Billion</td></tr></tbody></table><table><thead><tr><th>Attribute</th><th>Hospital Associated Labs</th></tr></thead><tbody><tr><td>Segment Value (2024E)</td><td>US$ 1.5 Billion</td></tr><tr><td>Growth Rate (2024 to 2034)</td><td>5.3% CAGR</td></tr><tr><td>Projected Value (2034F)</td><td>US$ 2.53 Billion</td></tr></tbody></table>

<p>随着全球范围内对癌症精准早期诊断重要性的日益认识，肺癌诊断的市场需求预计将不断增长，预计到2024年，该市场规模将达到298亿美元。全球肺癌诊断市场预计将以6.1%的复合年增长率（CAGR）扩张，并于2034年达到540亿美元。</p><table><thead><tr><th>报告属性</th><th>详细信息</th></tr></thead><tbody><tr><td>2024年预期肺癌诊断市场规模</td><td>29.8亿美元</td></tr><tr><td>2034年预测市场价值</td><td>54亿美元</td></tr><tr><td>2024年至2034年全球市场增长率</td><td>6.1% CAGR</td></tr><tr><td>2034年EGFR突变检测市场份额</td><td>28.2%</td></tr><tr><td>2024年至2034年韩国市场增长率</td><td>7.5% CAGR</td></tr><tr><td>2034年南亚及太平洋市场份额</td><td>21%</td></tr><tr><td>主要公司概览</td><td><ul><li>NeoGenomics Laboratories, Inc.</li><li>Illumina, Inc.</li><li>Danaher Corporation</li><li>Abbott Laboratories</li><li>Roche Holding AG</li><li>Quest Diagnostics Incorporated</li><li>Myriad Genetics, Inc.</li><li>Thermo Fischer Scientific, Inc.</li><li>NanoString Technologies, Inc.</li><li>QIAGEN N.V.</li></ul></td></tr></tbody></table><p>各国市场洞察</p><table><thead><tr><th>属性</th><th>美国</th></tr></thead><tbody><tr><td>2024年市场价值</td><td>9.15亿美元</td></tr><tr><td>2024年至2034年增长率</td><td>5.8% CAGR</td></tr><tr><td>2034年预测价值</td><td>16亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>中国</th></tr></thead><tbody><tr><td>2024年市场价值</td><td>2.339亿美元</td></tr><tr><td>2024年至2034年增长率</td><td>9.6% CAGR</td></tr><tr><td>2034年预测价值</td><td>5.867亿美元</td></tr></tbody></table><p>类别洞察</p><table><thead><tr><th>属性</th><th>EGFR突变检测</th></tr></thead><tbody><tr><td>2024年细分市场价值</td><td>8.793亿美元</td></tr><tr><td>2024年至2034年增长率</td><td>5.6% CAGR</td></tr><tr><td>2034年预测价值</td><td>15.2亿美元</td></tr></tbody></table><table><thead><tr><th>属性</th><th>医院关联实验室</th></tr></thead><tbody><tr><td>2024年细分市场价值</td><td>15亿美元</td></tr><tr><td>2024年至2034年增长率</td><td>5.3% CAGR</td></tr><tr><td>2034年预测价值</td><td>25.3亿美元</td></tr></tbody></table>